Trials
2 active
4 in total · 2 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Major Depressive Disorder (MDD), Depression in Adults, Depression - Major Depressive Disorder, Depression Disorders, Depression Disorder, Depression, Major Depressive Disorder
- Main trialPhase 3
- “The purpose of this study is to determine the efficacy, safety and tolerability of CYB003 compared to matching placebo as adjunctive treatment in patients with MDD. For more information about the EMBRACE study, including participating study locations, and to register your interest in learning more about participation, please visit the study website: https://embrace-mdd-trial.com/”In the company’s words, NCT06793397 on ClinicalTrials.gov
Other drugs for Major Depressive Disorder (MDD)
- SeltorexantJanssen Research & Development, LLC · Phase 3
- AzetukalnerXenon Pharmaceuticals Inc. · Phase 3
- LumateperoneIntra-Cellular Therapies, Inc. · Phase 3
- Mitizodone PhosphateSunshine Lake Pharma Co., Ltd. · Phase 2/3
- OsavampatorNeurocrine Biosciences · Phase 3
- DT120Definium Therapeutics US, Inc. · Phase 3
Coming up2
- 7 Jun 2027Phase 3 trial completes · ClinicalTrials.gov
- 6 Jun 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 7 Jun 2027 | A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder | |
| Phase 3Enrolling by invitation | 6 Jun 2028 | Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND) | |
| Phase 3Completed | 4 Sep 2026 | "A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder" | |
| Phase 1/2Completed | 16 Oct 2023 | A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive Disorder |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026